Charlotte Pahl
Directeur/Bestuurslid bij Reponex Pharmaceuticals A/S
Vermogen: 157 152 $ op 30-06-2024
Actieve functies van Charlotte Pahl
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Reponex Pharmaceuticals A/S
Reponex Pharmaceuticals A/S BiotechnologyHealth Technology Part of Pharma Equity Group A/S, Reponex Pharmaceuticals A/S operates as a Danish clinical stage biopharmaceutical company. The company is based in Hørsholm, Denmark. The company was founded in 2006. The CEO is Soren Nielsen. Reponex Pharmaceuticals was acquired by Pharma Equity Group A/S on March 24, 2023 for $109.83 million. | Directeur/Bestuurslid | - | - |
Loopbaan van Charlotte Pahl
Statistieken
Internationaal
Denemarken | 2 |
Operationeel
Director/Board Member | 1 |
Sectoraal
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Reponex Pharmaceuticals A/S
Reponex Pharmaceuticals A/S BiotechnologyHealth Technology Part of Pharma Equity Group A/S, Reponex Pharmaceuticals A/S operates as a Danish clinical stage biopharmaceutical company. The company is based in Hørsholm, Denmark. The company was founded in 2006. The CEO is Soren Nielsen. Reponex Pharmaceuticals was acquired by Pharma Equity Group A/S on March 24, 2023 for $109.83 million. | Health Technology |
- Beurs
- Insiders
- Charlotte Pahl
- Ervaring